ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

AstraZeneca Links With FibroGen

by Michael McCoy
August 5, 2013 | APPEARED IN VOLUME 91, ISSUE 31

AstraZeneca and FibroGen are joining to develop FG-4592, a FibroGen compound set to enter Phase III clinical trials as a treatment for anemia associated with chronic kidney disease and end-stage renal disease. AstraZeneca will pay San Francisco-based FibroGen $350 million plus future milestone payments of up to $465 million. FG-4592 is a small molecule that works through the body’s oxygen-sensing system to help produce red blood cells.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment